The University of Texas at Austin
UT Health Austin

Prevention and Treatment Options for COVID-19

The prevention and treatment options described below are available specifically for those individuals who meet criteria for use. Austin Public Health and community physicians are identifying and evaluating those patients who qualify for the prevention and treatment options described here. These options are available on a limited basis and will be prescribed to those patients who meet the use case for the appropriate treatment.

PREVENTION OPTION FOR SEVERELY IMMUNOCOMPROMISED INDIVIVIDUALS

Evusheld is used as a pre-exposure prevention for COVID-19 in people age 12 years and older who meet very specific criteria.

- moderate to severely compromised immune systems due to a medical condition or due to taking immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination (examples of such medical conditions or treatments can be found in the fact sheet for health care providers) or;

- a history of severe adverse reactions to a COVID-19 vaccine and/or component(s) of those vaccines, therefore vaccination with an available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended.

Evusheld has been granted Emergency Use Authorization by the Food and Drug Administration. It is currently only authorized for use in patients who are not currently affected by COVID-19 and have not been exposed to someone with COVID-19.

Evusheld is administered in two separate injections back-to-back and according to the FDA may be effective for pre-exposure prevention for up to 6 months. This prevention is not a substitute for vaccination and is not a treatment for individuals with COVID-19 or who have been exposed to COVID-19.

Possible side effects of Evusheld include: hypersensitivity reactions (including anaphylaxis), bleeding at the injection site, headache, fatigue and cough.

Individuals should speak to their doctor for more information about Evusheld and whether they qualify for this preventive treatment. For more information about Evusheld download this Fact Sheet for Patients and Caregivers.

The University of Texas at Austin
UT Health Austin

TREATMENT OPTIONS FOR PATIENTS WHO ARE SYMPTOMATIC, TEST POSITIVE AND AT HIGH RISK FOR DISEASE

- **PAXLOVID** (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use)
    - **Paxlovid** is used for the treatment of mild to moderate COVID-19 in people age 12 years and older who test positive and are at high risk for severe progression of the virus including hospitalization or death.

      Paxlovid has been granted Emergency Use Authorization by the Food and Drug Administration. It is not authorized for pre- or post-exposure of COVID-19, or as an initiation of treatment for those requiring hospitalization due to severe or critical COVID-19. This treatment is not a substitute for vaccination in individuals for whom COVID19 vaccination and booster dose are recommended.

      Paxlovid is administered orally by tablet.

      For more information about Paxlovid download this Fact Sheet for Patients and Caregivers.

- **SOTROVIMAB (Infusion)**
    - **Sotrovimab** is an investigational monoclonal antibody treatment used to treat mild-to-moderate symptoms of COVID-19 in people 12 years and older with positive results and who are at high for severe progression of the virus including hospitalization or death.

      Sotrovimab has been granted Emergency Use Authorization by the Food and Drug Administration.

      Sotrovimab is administered with 1 dose intravenously or through IV infusion for 30 minutes. Your provider will observe you for 1 hour after receiving treatment.

      For more information about Sotrovimab download this Fact Sheet for Patients and Caregivers.

- **MOLNUPIRAVIR**
    - **Molnupiravir** is an investigational medicine used to treat mild-to-moderate COVID-19 in adults 18 years and older:
        - with positive results of direct SARS-CoV-2 viral testing, and
        - who are at high risk for progressing to severe COVID-19 including hospitalization or death, and for whom other COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.

      Molnupiravir has been granted Emergency Use Authorization by the Food and Drug Administration for the treatment of mild-to-moderate COVID-19 in adults. It is not authorized for use:

- For people less than 18 years of age
- For the prevention of COVID-19
- For people needing hospitalization of COVID-19
- For longer than 5 consecutive days

Molnupiravir is administered by taking 4 capsules every 12 hours, for 5 consecutive days. It is important that patients complete the full five days of treatment with molnupiravir. The capsules should be stored at room temperature.

Safety Notices:

- *Molnupiravir may cause harm to your unborn baby. It is not known if molnupiravir will harm your baby if you take molnupiravir during pregnancy*.
- *Lactating patients should pump and discard breast milk until 4 days after the final dose.*
- *People of childbearing potential - pregnancy test if irregular menses/unsure of day 1 of last cycle/not consistently using effective contraception before or 4 days after treatment.*
- *Males who are sexually active with people of childbearing potential should use contraception during and three months after therapy.*

For more information about Molnupiravir download this Fact Sheet for Patients and Caregivers.

- **Remdesivir (Veklury)** - Not currently available in Austin as outpatient therapy as requires 3 days of IV treatment.